Ready 0
Contacted 0
Meeting 0
Due Diligence 0
Term Sheet 0
| Investor | Tier | Status | Actions |
|---|
Pending Follow-ups
No pending follow-ups
Today's Actions
Send Marc Violo LinkedIn DM
Apply to EIT Food accelerator
Apply to Big Idea Ventures
Quick Outreach
Marc Violo DM
LinkedIn - Ready
Content partnership angle for MycoStories founder.
Cold Email - VC
Email - 3 Versions
Direct pitch, portfolio alignment, and thesis-first approaches.
Warm Intro Request
Email - 4 Versions
Templates for asking mutual connections for introductions.
Follow-Up Sequence
Email - 4-Touch
Day 0, 4, 10, 21 follow-up sequence with value-adds.
Accelerator App
BIV + EIT Food
Pre-written content for accelerator applications.
Strategic Partner
Corporate VCs
Outreach for corporate VCs and strategic investors.
Grants & Accelerators
| Program | Amount | Deadline | Status | Eligibility | Actions |
|---|
Legal & Compliance Tracker
SEC - Securities Compliance
Exemption
Reg D 506(b)
Up to 35 non-accredited + unlimited accredited investors
Form D Filing
Within 15 days
File on SEC EDGAR after first sale of securities
CA State Filing
DFPI Notice
Within 15 business days of first CA sale
FDA - Product Compliance
Regulatory Pathway
DSHEA (Dietary Supplement)
No pre-market approval required. Structure/function claims only.
Manufacturing Standard
cGMP Required
21 CFR Part 111 - Current Good Manufacturing Practices
California State Requirements
Processed Food Registration
CA PFR - $100 fee
Contact: Melissa.Vasquez@cdph.ca.gov
DFPI Securities Notice
Within 15 business days
California Department of Financial Protection and Innovation
Compliance Checklist
Market Intelligence
Total Addressable Market
$13.2B
2026 estimate
Projected TAM (2031)
$20.74B
9.45% CAGR
Extract COGS
$2.68/g
40-55% gross margin
Key Industry Deals
KAAPA Biotech - EUR 9M Seed Round
Nov 2025 | Led by PeakBridge + Zintinus + Applied Food Sciences
Validates functional mushroom extraction as investable asset class. KAAPA = Finland-based, FA = US equivalent.
MycoWorks Series D
Backed by Novo Holdings, Valor Equity Partners
Mycelium materials company. Different application (materials vs extracts) but validates fungi biotech thesis.
NFX Bio Fund IV - $325M
2025 | Seed-stage bio platform fund
Active deployment in bio companies. Good timing for our raise.
Competitive Landscape
| Company | Focus | Stage | Differentiation |
|---|---|---|---|
| KAAPA Biotech | Mushroom extraction (EU) | Seed (EUR 9M) | EU-based. FA = US market. Different geography. |
| Real Mushrooms | Consumer supplements | Established | Consumer brand, not B2B infrastructure. Potential customer. |
| Nammex | Wholesale extracts | Established | China-sourced. FA = domestic US, circular economy model. |
| MycoTechnology | Mushroom biotech | Series C | Fermentation platform, not extraction. Different tech approach. |
| Om Mushrooms | Consumer supplements | Established | Consumer brand. Vertically integrated. Potential customer for FA ingredients. |
FungAlchemy Operating Metrics
$10-15K
Monthly Revenue
<5%
Capacity Utilized
170 lbs
Daily Capacity
600+ lbs
Scaled Target
$2.68
COGS/gram
40-55%
Gross Margin
$600K-1.2M
Y1 Revenue Target
93%
Zero-Cost Feedstock
Data Room Tracker
Core Documents
Executive Summary
Pitch Deck
Business Plan
Financial
Financial Projections
COGS Analysis
Cap Table
Legal
Articles of Incorporation
Operating Agreement
IP Documentation
Market & Product
Market Research
Competitive Analysis
Customer Testimonials
Operations
SOPs
Quality Certifications
Supply Agreements
Team
Founder Bio
Advisory Board
Org Chart
Document Distribution Log
No documents sent yet. Use the investor detail view to log document sends.
Pipeline Analytics
Conversion Funnel
Avg Days in Stage
-
Total Pipeline Value
-
Active Conversations
-
Recent Activity Summary
Activity Log
No activity yet